Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19

Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19

Introduction A novel coronavirus, designated SARS-CoV-2, caused an international outbreak of a respiratory illness, termed COVID-19 in December 2019. There is a lack of specific therapeutic agents based on evidence for this novel coronavirus infection; however, several medications have been evaluate...

Full description

Bibliographic Details
Main Authors: Majed Al-Jeraisy, Ahmed Alaskar, Majid Alshamrani, Mohammad Bosaeed, Ahmad Alharbi, Mohammad Hussein, Mohammed Abalkhail, Khizra Sultana, Abrar Musattat, Hajar Alqahtani, Ebrahim Mahmoud, Adel Alothman, Abdulrahman Alsaedy, Omar Aldibasi, Khalid Alhagan, Abdullah Mohammed Asiri, Sameera AlJohani
Format: Article
Language:English
Published: BMJ Publishing Group 2021-04-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/11/4/e047495.full

Internet

https://bmjopen.bmj.com/content/11/4/e047495.full

Similar Items